i
This Document Has Been Replaced By: Prevention of hepatitis A through active or passive immunization; recommendations of the Advisory Committee on Immunization Practices (ACIP)
Superseded
This Document Has Been Replaced By: Prevention of hepatitis A through active or passive immunization; recommendations of the Advisory Committee on Immunization Practices (ACIP)
Prevention of hepatitis A through active or passive immunization : recommendations of the Advisory Committee on Immunization Practices (ACIP)
-
December 27, 1996
Source: MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control. 1996; 45(RR-15):1-30. -
Personal Author:
-
Corporate Authors:
-
Description:This report provides recommendations for use of the newly licensed hepatitis A vaccines (HAVRIX, manufactured by SmithKline Beecham Biologicals, and VAQTA, manufactured by Merck & Company, Inc.) in persons > or = 2 years of age and updates previous recommendations for use of immune globulin (IG) for protection against hepatitis A (superseding MMWR 1990;39[No. RR-2]:1-5). For preexposure protection, hepatitis A vaccine can now be used instead of IG in many circumstances; for postexposure prophylaxis, the recommendations for IG use are unchanged.
-
Content Notes:December 27, 1996.
The following CDC staff members prepared this report:Craig N. Shapiro, Beth P. Bell, Harold S. Margolis, Division of Viral and Rickettsial Diseases,National Center for Infectious Diseases.
Includes bibliographical references (p. 26-30).
Man-HueiChang/Dholtzman
2/21/2014
-
Subjects:
-
Pubmed ID:9005304
-
Document Type:
-
Genre:
-
Place as Subject:
-
Location:
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type:
-
No Additional Files
Details:
Supporting Files
More +